Introduction: Acute myeloid leukemia (AML) is a difficult disease to treat in resource limited settings. Data from India is limited to identify trends or shortcomings and plan remedial strategies. Objective: To analyze the clinical profile and outcome in children with AML treated with daunorubicin- based induction protocol in a Pediatric oncology centre.

Methodology: This study looks at the outcomes of 27 patients with pediatric AML treated at our centre from January 2018 and June 2020. They were treated with daunorubicin based induction followed by consolidation with high dose cytarabine.

Results: The complete remission rate in this study is 66.7%. Toxicity related deaths were seen in deaths were seen in 25.9% cases. The relapse rate is 22.2%. Event free survival (EFS) in the cohort at 2.5 years was 51.8%.

Conclusion: This study demonstrates good EFS with the use of daunorubicin based protocol in resource limited settings as compared to previously reported studies. The toxicity related deaths specially in induction can be further reduced if we can ensure early referral of patients and prompt treatment.

Keywords: Pediatric Acute Myeloid Leukaemia; Survival; Outcome; Daunorubicin

References

1. Kulkarni KP and Marwaha RK. “Childhood acute myeloid leukemia: an Indian perspective”. Pediatric Hematology and Oncology 28 (2011): 257-268.
2. Creutzig U., et al. “Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials”. Leukemia 19 (2005): 2030-2042.
3. Smith FO., et al. “Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891”. Leukemia 19 (2005): 2054-2062.
4. Gupta N., et al. “Treatment of acute myeloid leukemia in children: Experience from a tertiary care hematology centre in India”. Indian Journal of Pediatrics 78 (2011): 1211-1215.
5. Yadav SP., et al. “Pediatric acute myeloid leukemia: Final frontier for pediatric oncologists in developing world”. Pediatric Hematology and Oncology 28 (2011): 647-648.
6. Philip C., et al. “Acute myeloid leukaemia: Challenges and real world data from India”. British Journal of Haematology 170 (2015): 110-117.
7. Bahl A., et al. “Long-term outcomes for patients with acute myeloid leukemia: A single-center experience from AIIMS, India”. Asia-Pacific Journal of Clinical Oncology 11 (2015): 242-252.
8. Radhakrishnan V., et al. “Acute myeloid leuk-emia in children: Experience from tertiary cancer centre in India”. Indian Journal of Hematology and Blood Transfusion 32 (2016): 257-261.
9. Manola KN. “Cytogenetics of pediatric acute myeloid leukemia”. European Journal of Haematology 83 (2009): 391-405.
10. Tyagi A., et al. “Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia”. Indian Pediatrics6 (2018): 469-473.

Citation

Citation: Dipshikha Maiti and Pritam Roy. “Acute Myeloid Leukemia in Children in Resource Limited Setting: Experience from a Tertiary Paediatric Oncology Center of Eastern India”.Acta Scientific Cancer Biology 8.7 (2024): 16-19.

Copyright

Copyright: © 2024 Dipshikha Maiti and Pritam Roy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.